AcneJDD HighlightsRosacea

The Latest Research & Discoveries in Acne, Rosacea, Anti-Aging, and Medical Dermatology

Dermatology News

JDD Highlights

The June issue of the Journal of Drugs in Dermatology is available now. This month, we focus on Acne and Rosacea, with special features on Public Health, Anti-aging, Aesthetic, and Medical Dermatology.

Read the JDD Now

Acne, Rosacea, Public Health, Anti-Aging, Aesthetic, and Medical Dermatology

The June issue of the Journal of Drugs in Dermatology is available now. This month, we focus on Acne and Rosacea, with special features on Public Health, Anti-aging, Aesthetic, and Medical Dermatology.

Article Highlights

Editor's Picks

You May Also Like

Journal of Drugs in Dermatology JDD featuring Dr. Jacob Beer in JDD Re:View, a discussion of JDD articles and specific topics. This article highlights Aesthetics Is Changing. Here’s What We’re Seeing?AestheticsFeatured ArticlesJDD Re:ViewLatest News
January 29, 2026

JDD Re:View With Dr. Beer

Aesthetics Is Changing. Here’s What We’re Seeing? Most dermatologists have experienced a shift in patient preferences over the past several years. There is a shift toward a minimalist, natural appearance.…
Journal of Drugs in Dermatology JDD Article about Racial Disparities in United States Clinical Trial Enrollment for Mycosis Fungoides and Sézary SyndromeFeatured ArticlesLatest NewsSkin of Color
January 28, 2026

Racial Disparities in United States Clinical Trial Enrollment for Mycosis Fungoides and Sézary Syndrome

Trials fall short on representation - Black patients underenrolled in MF/SS studies The February issue of JDD features a review of completed US interventional trials for mycosis fungoides and Sézary syndrome…
Journal of Drugs in Dermatology JDD Article about Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab. Image shows thumb and nail or patient.Case ReportsFeatured ArticlesLatest News
January 26, 2026

Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab

Case report shows dual IL‑17A/F blockade produced striking clinical and functional gains within one month in refractory ACH The February 2026 JDD issue features a case report about a 67‑year‑old…

Leave a Reply